Emerging evidence implicates CHAF1B is highly expressed across diverse malignancies, including leukemia, high-grade gliomas, melanomas, endometrial tumors, prostate cancer, and so forth 12-15, 17, 18, 33, 34. Here, CHAF1B is linked to central nervous system cancer.